Back

Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection

Lu, Z.; Laing, E. D.; Pena-Damata, J.; Pohida, K.; Tso, M. S.; Samuels, E. C.; Epsi, N. J.; Dorjbal, B.; Lake, C.; Richard, S. A.; Maves, R. C.; Lindholm, D. A.; Rozman, J.; English, C.; Huprikar, N.; Mende, K.; Colombo, R. E.; Colombo, C. J.; Broder, C. C.; Ganesan, A.; Lanteri, C. A.; Agan, B. K.; Tribble, D.; Simons, M. P.; Dalgard, C. L.; Blair, P. W.; Chenoweth, J.; Pollett, S. D.; Snow, A. L.; Burgess, T. H.; Malloy, A. M.

2021-08-11 immunology
10.1101/2021.08.11.455984 bioRxiv
Show abstract

BackgroundCharacterizing the longevity and quality of cellular immune responses to SARS-CoV-2 is critical to understanding immunologic approaches to protection against COVID-19. Prior studies suggest SARS-CoV-2-specific T cells are present in peripheral blood 10 months after infection. Further analysis of the function, durability, and diversity of the cellular response long after natural infection, over a wider range of ages and disease phenotypes, is needed to further identify preventative and therapeutic interventions. MethodsWe identified participants in our multi-site longitudinal, prospective cohort study 12-months post SARS-CoV-2 infection representing a range of disease severity. We investigated the function, phenotypes, and frequency of T cells specific for SARS-CoV-2 using intracellular cytokine staining and spectral flow cytometry. In parallel, the magnitude of SARS-CoV-2-specific antibodies was compared. ResultsSARS-CoV-2-specific antibodies and T cells were detected at 12-months post-infection. Severity of acute illness was associated with higher frequencies of SARS-CoV-2-specific CD4 T cells and antibodies at 12-months. In contrast, polyfunctional and cytotoxic T cells responsive to SARS-CoV-2 were identified in participants over a wide spectrum of disease severity. ConclusionsOur data show that SARS-CoV-2 infection induces polyfunctional memory T cells detectable at 12-months post-infection, with higher frequency noted in those who originally experienced severe disease.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Brain, Behavior, and Immunity
105 papers in training set
Top 0.1%
10.6%
2
The Journal of Infectious Diseases
182 papers in training set
Top 0.2%
9.3%
3
Frontiers in Immunology
586 papers in training set
Top 0.7%
8.6%
4
Immunology
29 papers in training set
Top 0.1%
6.5%
5
The Journal of Immunology
146 papers in training set
Top 0.2%
4.9%
6
PLOS ONE
4510 papers in training set
Top 31%
4.9%
7
ImmunoHorizons
21 papers in training set
Top 0.1%
4.4%
8
Viruses
318 papers in training set
Top 2%
2.9%
50% of probability mass above
9
BMC Medicine
163 papers in training set
Top 2%
2.8%
10
mBio
750 papers in training set
Top 6%
2.7%
11
Clinical Infectious Diseases
231 papers in training set
Top 2%
2.4%
12
Cell Reports Medicine
140 papers in training set
Top 2%
2.1%
13
Nature Communications
4913 papers in training set
Top 50%
1.7%
14
iScience
1063 papers in training set
Top 14%
1.7%
15
Open Forum Infectious Diseases
134 papers in training set
Top 1%
1.7%
16
Clinical & Translational Immunology
22 papers in training set
Top 0.1%
1.5%
17
Cell Reports
1338 papers in training set
Top 26%
1.5%
18
Nature Immunology
71 papers in training set
Top 1%
1.5%
19
Science Immunology
81 papers in training set
Top 1%
1.5%
20
JCI Insight
241 papers in training set
Top 5%
1.2%
21
Mucosal Immunology
42 papers in training set
Top 0.2%
1.1%
22
Journal of Virology
456 papers in training set
Top 3%
1.1%
23
Allergy
23 papers in training set
Top 0.4%
1.0%
24
Clinical Immunology
21 papers in training set
Top 0.4%
1.0%
25
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
26
Scientific Reports
3102 papers in training set
Top 70%
0.9%
27
Immunology & Cell Biology
11 papers in training set
Top 0.2%
0.8%
28
EBioMedicine
39 papers in training set
Top 0.9%
0.8%
29
PLOS Pathogens
721 papers in training set
Top 9%
0.8%
30
Journal of Medical Virology
137 papers in training set
Top 4%
0.8%